You are here: Industry Insights > Market News > Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

pharmaceutical-technologyJuly 10, 2017

Tag: ImmunoPrecise Antibodies , Pharmaceuticals International

Favorites

Valeant Pharmaceuticals International has announced the sale of its subsidiary Dendreon Pharmaceuticals for $819.9m to Sanpower Group.

The divestiture is part of the Canadian company’s plans to simplify its business and reduce debt.

ImmunoPrecise Antibodies has announced the private placement of four million shares priced at C$1 ($0.77) each to raise C$4m ($3.08m).

ImmunoPrecise is a Canadian-based provider of antibodies that plans to use the funds to acquire U-Protein Express.

Previous:Celgene to acquire rights to BeiGene’s PD-1 inhibitor for solid tumour cancers

Next:M&As this week: Acino Pharma, Oriola-KD Corporation, ImmunoPrecise Antibodies

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Deals this week: Valeant Pharmaceuticals International, ImmunoPrecise Antibodies

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>